<DOC>
	<DOCNO>NCT02347722</DOCNO>
	<brief_summary>The purpose study evaluate exist biomarkers see use accurately diagnose etiology heart failure .</brief_summary>
	<brief_title>Biomarkers Classify Heart Failure</brief_title>
	<detailed_description>This cohort study consist 2 patient cohort . The first cohort study retrospectively , use exist blood sample different biobanks . Biomarkers measure matched etiology previously diagnose heart failure biomarker panel heart failure expert . This cohort consist 100 patient ( 1 ) ischemic cardiomyopathy , ( 2 ) dilate cardiomyopathy ( 3 ) diastolic heart failure . Blood sample analyze novel biomarkers . Investigators seek biomarker candidate ( ) alone combination predict category heart failure etiology 85 % accuracy low level reclassification . A panel heart failure expert assemble , appropriate cut-off value determine . Once goal achieve , prospective study go ahead . In second cohort , biomarkers measure use diagnose etiology heart failure subject . This diagnosis compare diagnosis result usual diagnostic test . Investigators recruit 450 patient admitted hospital outpatient clinic recently diagnose heart failure ( &lt; 2 year ) test different biomarkers . Using biomarker value , investigator predict heart failure etiology objective manner . The patient undergo definitive etiological workup usual establish actual etiology heart failure . The duration typical etiological workup 3 day hospitalize patient 8 week patient admit outpatient clinic . The predictive accuracy new heart failure panel compare clinical assessment . Investigators perform cost-modeling term potential saving avoid unnecessary coronary angiography perfusion scan typical mixed cohort heart failure patient base marker determine etiology . A sub-study added recruit 60-75 newly diagnose ( within 3 month ) patient admit acute heart failure . These patient serial biomarkers measure within 24 hour admission , 3-4 day admission , discharge , 1 , 3 6 month post discharge hospital . These serial biomarkers allow u assess effect heart failure treatment biomarkers .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patients admit symptomatic heart failure , diagnose within 2 year . Diagnosis congestive heart failure use modify Framingham criterion : Simultaneous presence least 2 major criterion 1 major criterion conjunction 2 minor criterion previous clear diagnosis heart failure . Major criterion : Paroxysmal nocturnal dyspnea orthopnea Neck vein distention Rales/Crackles ( &gt; 10 cm base lung ) Acute pulmonary edema S3 gallop Increased central venous pressure ( &gt; 16 cm H2O right atrium ) Hepatojugular reflux Weight loss &gt; 4.5 kg 5 day response treatment Echocardiographic leave ventricular dysfunction Minor criterion : Bilateral ankle edema Nocturnal cough Dyspnea exertion Hepatomegaly Pleural effusion Weight loss &gt; 4.5 kg cause heart failure factor treatment CHF could contribute weight loss Tachycardia ( heart rate &gt; 120 beats/min ) Minor criterion acceptable attribute another medical condition ( pulmonary hypertension , chronic lung disease , cirrhosis , ascites , nephrotic syndrome ) . Patients unable provide blood sample Patients unable provide consent Patient life expectancy le 6 month , major comorbidities . Any significant disease disorder , opinion Investigator , may either put participant risk participation trial , may influence result trial , participant 's ability participate trial . Participants participate another research trial involve investigational product past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>biomarkers</keyword>
	<keyword>diagnosis</keyword>
	<keyword>etiology heart failure</keyword>
</DOC>